BAY-549
Probe criteria
| Inhibitor/agonist potency: goal is < 100 nM (IC50, Kd>/sub>) | Surpasses criterion: High potency in biochemical assay: ROCK1 (h) (IC50 = 0.6 nM), ROCK2 (h) (IC50 = 1.1 nM), ROCK2 (m) (IC50 = 2.4 nM), ROCK2 (r) (IC50 = 0.8 nM) |
| Selectivity within target family: > 30-fold | Surpasses criterion: selectivity >250 fold vs all other kinases (Upstate panel @ 10 µM closest hits: NTRK1 IC50 = 252 nM, FLT3 IC50 = 303 nM) |
| Selectivity outside target family | LeadProfilingScreen closest off-targets @ 10 µM: SLC6A3 (DAT, human) IC50 = 0.4 µMClean PDSP scan except for activity on OPRK1 (Ki = 187.33 nM) and SIGMAR1 (Ki = 6765.5 nM) |
| On target cell activity for cell-based targets: goal is < 1 µM IC50/EC50 | Surpasses criterion: Mechanistic tissue assay (Arteria Saphena rabbit): IC50 = 65 nM |
| On target cell activity for secreted targets: appropriate alternative such as mouse model or other mechanistic biological assay | Surpasses criterion: Suitable pharmacokinetic profile for in vivo studies; in vivo efficacy in experimental animal models (rat, dog) |
| Control compound (100 times less potent than the probe) | Surpasses criterion: ROCK2 (h): IC50 = 17.7 nM; Clean PDSP scan except for activity on OPRK1 (Ki = 390.57 nM) |